|
|
|
| Changes in Serum Cysc SAA Levels and Their Correlation with Cognitive Impairment in Parkinson's Disease Patients |
| LIN Baoping, ZHU Zuoquan, GUI Xin, et al |
| The First People's Hospital of Jingzhou, Hubei Jingzhou 434000, China |
|
|
|
|
Abstract Objective: To analyze the changes in levels of serum cystatin C (CysC) and SAA in patients with Parkinson’s disease (PD) and their relationship with cognitive impairment.Methods: Patients who received treatment and physical examination in the hospital from August 2019 to August 2023 were selected as the research subjects, including 150 PD patients as the case group and 90 healthy volunteers as the control group. Cognitive function was assessed using Montreal Cognitive Assessment Scale (MoCA). The general data, serum CysC and SAA levels, and MoCA scores were compared. The levels of CysC and SAA were compared among patients with different Hoehn and Yahr (H-Y) stages. The CysC and SAA levels were compared between the case group and the control group. The correlation of CysC and SAA with H-Y staging and MoCA score was analyzed using Pearson analysis.Results: The levels of CysC and SAA in the case group were higher while the MoCA score was lower than in the control group (P<0.05). CysC and SAA revealed the control group < the early PD group < the middle and late PD group, while MoCA score revealed the control group > the early PD group > the middle and late PD group (P<0.05). CysC and SAA levels revealed the control group < normal cognition group < cognitive impairment group (P<0.05). The levels of serum CysC and SAA in PD patients were positively correlated with H-Y staging (r=0.610, 0.565, P<0.05), and were negatively associated with MoCA score (r=-0.352, -0.533, P<0.05).Conclusion: The levels of CysC and SAA in the serum of PD patients are increased. With the increase of H-Y stage, the levels of CysC and SAA rose while the MoCA score decreased. The levels of serum CysC and SAA in PD patients were positively correlated with H-Y staging and negatively correlated with MoCA score.
|
|
|
|
|
|
[1] Paik J.Levodopa Inhalation Powder: A Review In Parkinson's Disease[J].Drugs,2020,80(8):821-828.
[2] 尹继续.帕金森症合并痴呆与血管性痴呆认知功能障碍及焦虑抑郁情绪的比较[J].湖南中医药大学学报,2016,36(2):837.
[3] 张婧,徐钧,蔡红星,等.胱抑素C水平与急性脑梗死神经功能缺损评估及预后相关研究[J].皖南医学院学报,2020,39(3):221-224.
[4] Badolato,R.Serum amyloid A is a chemoattractant: induction of migration,adhesion,and tissue infiltration of monocytes and polymorphonuclear leukocytes.[J].The Journal of Experimental Medicine,2018,180(1):203-209.
[5] 王若丹,周瑜,段玮,等.血清淀粉样蛋白A水平变化与帕金森病患者认知功能障碍的关系[J].疑难病杂志,2018,17(2):121-124.
[6] 王会,王玉才.帕金森病痴呆与阿尔茨海默病的认知功能和精神行为症状比较[J].中国神经精神疾病杂志,2018,44(2):70-74.
[7] 杨仕林,吴云成.帕金森病痴呆相关临床研究进展[J].中国现代神经疾病杂志,2017,17(2):95-100.
[8] 梁涛,吴苏源,梅思雨,等.血清尿酸,同型半胱氨酸及淀粉样蛋白A与帕金森病的相关性研究[J].临床血液学杂志,2023,36(2):81-86.
[9] 张家和,柯开富,施建生,等.血尿酸,CysC及Hcy与老年帕金森病患者病程及疾病严重程度相关性分析[J].中国医药导报,2022,19(5):82-85.
[10] 马婷婷,胡鸿炜,林慧怡,等.帕金森病人血清胱抑素C水平,尿酸变化与病情分期,认知障碍,运动功能的相关性研究[J].蚌埠医学院学报,2022,47(8):1043-1047.
[11] 孙妮,时晶,刘贵安.血清EGF YKL-40 SAA水平与帕金森病患者认知障碍的相关性分析[J].河北医学,2021,27(7):1090-1093. |
|
|
|
2024, Vol. 30 
